2017
DOI: 10.1080/01913123.2016.1275909
|View full text |Cite
|
Sign up to set email alerts
|

In vitro activity of a partially purified and characterized bark extract ofCastanea sativa Mill. (ENC®) againstChlamydiaspp

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 35 publications
0
2
0
Order By: Relevance
“…Papa et al demonstrated that CSWE reduced all Chlamydia strains tested at 1 µg/mL, while SMAP-29 at 10 µg/mL caused a reduction in the infectivity of C. trachomatis and C. pneumoniae. A strong reduction in the infectivity of C. trachomatis, C. pneumoniae, and C. abortus was achieved with a CSWE concentration of 10 µg/mL, while their infectivity was almost inhibited at a CSWE concentration of 100 µg/mL [68]. The study by Brizi et al investigated the neuroprotective effect of CSWE in in vitro models of oxidative stress injury.…”
Section: Anti-inflammatory Activitymentioning
confidence: 99%
“…Papa et al demonstrated that CSWE reduced all Chlamydia strains tested at 1 µg/mL, while SMAP-29 at 10 µg/mL caused a reduction in the infectivity of C. trachomatis and C. pneumoniae. A strong reduction in the infectivity of C. trachomatis, C. pneumoniae, and C. abortus was achieved with a CSWE concentration of 10 µg/mL, while their infectivity was almost inhibited at a CSWE concentration of 100 µg/mL [68]. The study by Brizi et al investigated the neuroprotective effect of CSWE in in vitro models of oxidative stress injury.…”
Section: Anti-inflammatory Activitymentioning
confidence: 99%
“…The emergence of antibiotic resistance should be the driver for development and application of new antichlamydials in veterinary medicine. Efforts for these are already underway, including in animals (Lawrence et al, 2016), exploiting a range of strategies to target Chlamydia -specific cell structures and/or known virulence factors (Ur-Rehman et al, 2012; Marti et al, 2014; Koroleva et al, 2015; Rahn et al, 2016; Donati et al, 2017; Papa et al, 2017; Figure 1). Regardless of years of research into chlamydia control through immunoprophylaxis there are almost no viable chlamydial vaccines to date.…”
Section: Future Directions and Concluding Remarksmentioning
confidence: 99%